GT Biopharma (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the company’s proprietary natural killer (“NK”) cell engager, TriKE(TM) protein biologic technology platform, has released fourth-quarter and year-end financial and company results for the period ended Dec. 31, 2020. Company highlights noted in the announcement included entering into a GMP manufacturing partnership with Cytovance; the initiation of manufacturing of additional solid tumor TriKE for lung, breast, ovarian and gastrointestinal cancer programs in preparation for FDA clinical trials; and enhancing and expanding the company’s board of directors. In addition, the company completed a successful listing on NASDAQ and closed on a $28.7 million public offering, which resulted in GT Biopharma having more than $30 million in the bank. “2020 was a year of robust clinical progress and milestone achievements for GT Biopharma, which allowed us to accomplish a major corporate milestone in listing GT Biopharma on NASDAQ at the beginning of 2021,” said GT Biopharma chair and CEO Anthony J. Cataldo in the press release. “The emerging data from our GTB-3550 TriKE program in hematological malignancies, MDS and AML, are encouraging in both safety and efficacy profiles. The ongoing data profile has demonstrated significant differences from all other NK cell therapies and NK engager companies, making TriKE a monotherapy, off-the-shelf platform therapeutic. TriKE exerts its therapeutic effect without the need for outside assistance in the form of combination therapies or the addition of supplemental progenitor-derived or autologous/allogenic NK cells. As a result, TriKE therapy cost to patients will be far superior, significantly more economic than progenitor-derived or autologous/allogenic NK cell therapy companies’ offerings. Additionally, the results generated from the GTB-3550 TriKE clinical trial reinforces its versatility, providing a clear rationale to proceed with additional programs in solid tumor and hematologic cancers.”
To view the full press release, visit https://ibn.fm/lPpaE
About GT Biopharma Inc.
GT Biopharma is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary TriKE NK cell engager platform. The company’s TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. For more information, please visit www.GTBiopharma.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.